Abpro Holdings Inc (ABP)

$3.50 -0.06 (-1.69%)
Market Cap 9.67M
Revenue (ttm) 180,000.00
Net Income (ttm) -7.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,016.67%
Debt to Equity Ratio 0.00
Volume 7,100
Avg Vol 22,672
Day's Range N/A - N/A
Shares Out 2.72M
Stochastic %K 6%
Beta 0.02
Analysts Strong Buy
Price Target $2.00

Company Profile

Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific anti...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 396 5890
Website: abpro.co
Address:
68 Cummings Park Drive, Woburn, United States
AnchoredWealth
AnchoredWealth Jan. 16 at 11:24 AM
$ABP Just checked, still deficient.
1 · Reply
AnchoredWealth
AnchoredWealth Jan. 16 at 11:08 AM
$ABP Impressive!
0 · Reply
AnchoredWealth
AnchoredWealth Jan. 16 at 11:07 AM
$ABP Any news regarding compliance?
1 · Reply
NiX2000
NiX2000 Jan. 15 at 9:58 PM
$ABP ATL again. MC is $10M. Either OS is wrong cuz of dilution for months and the MC is higher, or they’ll get delisted and then bankruptcy. They had better have some catalyst soon or they’re f-ed.
0 · Reply
f1rew1re
f1rew1re Jan. 15 at 2:36 PM
$ABP institutional investors will come when most of the private investors lost patience. Let’s see
0 · Reply
f1rew1re
f1rew1re Jan. 15 at 1:13 PM
$ABP https://www.globenewswire.com/news-release/2026/01/15/3219396/0/en/Abpro-s-Lead-Program-ABP-102-Featured-in-Celltrion-Presentation-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html
0 · Reply
TU6637
TU6637 Jan. 13 at 8:49 PM
$ABP paytience 💰
0 · Reply
NiX2000
NiX2000 Jan. 12 at 5:29 PM
$ABP slow death
0 · Reply
f1rew1re
f1rew1re Jan. 9 at 4:08 PM
$ABP seems like nobody interested in ABP at the moment…
0 · Reply
f1rew1re
f1rew1re Jan. 7 at 5:20 PM
$ABP everything happening with this low volume is meaningless 🥱
0 · Reply
Latest News on ABP
Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 7:00 AM EST - 2 days ago

Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

Jan 6, 2026, 7:00 AM EST - 11 days ago

Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

Dec 15, 2025, 7:00 AM EST - 4 weeks ago

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

Dec 9, 2025, 7:00 AM EST - 5 weeks ago

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

Nov 4, 2025, 9:15 AM EST - 2 months ago

Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025

Nov 3, 2025, 7:00 AM EST - 2 months ago

Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Apr 27, 2025, 2:00 PM EDT - 9 months ago

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 10 months ago

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

Abpro Statement on the Departure of Former CEO Ian Chan

Mar 10, 2025, 6:34 PM EDT - 11 months ago

Abpro Statement on the Departure of Former CEO Ian Chan

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

Dec 12, 2024, 4:05 PM EST - 1 year ago

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

AnchoredWealth
AnchoredWealth Jan. 16 at 11:24 AM
$ABP Just checked, still deficient.
1 · Reply
AnchoredWealth
AnchoredWealth Jan. 16 at 11:08 AM
$ABP Impressive!
0 · Reply
AnchoredWealth
AnchoredWealth Jan. 16 at 11:07 AM
$ABP Any news regarding compliance?
1 · Reply
NiX2000
NiX2000 Jan. 15 at 9:58 PM
$ABP ATL again. MC is $10M. Either OS is wrong cuz of dilution for months and the MC is higher, or they’ll get delisted and then bankruptcy. They had better have some catalyst soon or they’re f-ed.
0 · Reply
f1rew1re
f1rew1re Jan. 15 at 2:36 PM
$ABP institutional investors will come when most of the private investors lost patience. Let’s see
0 · Reply
f1rew1re
f1rew1re Jan. 15 at 1:13 PM
$ABP https://www.globenewswire.com/news-release/2026/01/15/3219396/0/en/Abpro-s-Lead-Program-ABP-102-Featured-in-Celltrion-Presentation-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html
0 · Reply
TU6637
TU6637 Jan. 13 at 8:49 PM
$ABP paytience 💰
0 · Reply
NiX2000
NiX2000 Jan. 12 at 5:29 PM
$ABP slow death
0 · Reply
f1rew1re
f1rew1re Jan. 9 at 4:08 PM
$ABP seems like nobody interested in ABP at the moment…
0 · Reply
f1rew1re
f1rew1re Jan. 7 at 5:20 PM
$ABP everything happening with this low volume is meaningless 🥱
0 · Reply
Tunes444
Tunes444 Jan. 7 at 3:46 PM
$ABP News flow has been pretty decent recently... Cannot complain on that front
0 · Reply
devilartist
devilartist Jan. 7 at 7:12 AM
$ABP I hope the trading volume will increase
1 · Reply
Diggersen
Diggersen Jan. 6 at 8:42 PM
$ABP Sooner or later this will blast off like $DRUG
1 · Reply
f1rew1re
f1rew1re Jan. 6 at 7:57 PM
$ABP still not much volume - once the volume kicks in it could get interesting 🙂
0 · Reply
DARKP00L
DARKP00L Jan. 6 at 7:29 PM
$ABP 14:24 on Jan. 06 2026 Abpro Holdings shares are trading higher after the company announced that the FDA has cleared the Investigational New Drug application for its lead multispecific antibody oncology program ABP-102 / CT-P72. #tradeideas
0 · Reply
f1rew1re
f1rew1re Jan. 6 at 1:57 PM
$ABP https://www.globenewswire.com/news-release/2026/01/06/3213468/0/en/Abpro-and-Celltrion-Inc-Announce-U-S-FDA-IND-Clearance-for-Lead-Multispecific-Antibody-Cancer-Candidate-ABP-102-CT-P72.html
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 6 at 1:49 PM
$ABP (+5.4% pre) Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance https://ooc.bz/l/88707
0 · Reply
DARKP00L
DARKP00L Jan. 6 at 12:19 PM
$ABP 07:09 on Jan. 06 2026 Abpro and Celltrion to Start Global Trial of Targeted HER2+ Cancer Antibody in Early 2026 #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 6 at 12:14 PM
$ABP 07:09 on Jan. 06 2026 Abpro and Celltrion to Start Global Trial of Targeted HER2+ Cancer Antibody in Early 2026 #tradeideas
0 · Reply
Jackpot233
Jackpot233 Jan. 6 at 12:13 PM
$ABP
0 · Reply
DARKP00L
DARKP00L Jan. 6 at 12:12 PM
$ABP 07:09 on Jan. 06 2026 Abpro and Celltrion to Start Global Trial of Targeted HER2+ Cancer Antibody in Early 2026 #tradeideas
0 · Reply
f1rew1re
f1rew1re Jan. 6 at 6:57 AM
$ABP once it is fully compliant again the volume will come back. Just a matter of time in my opinion.
0 · Reply